Tag Archives: what’s the crack podcast

As more countries and jurisdictions are relaxing their laws around cannabis, many questions have arisen. Will legalisation affect potency? Could some types of cannabis actually reduce psychosis? What are the choices in cannabis legislation, is it just prohibition or legalisation? And if cannabis is legalised, will everyone start using it? These are just a few of the questions answered by myself and two other researchers from King’s College London in the fourth episode of a new podcast; What’s the Crack.

We created the podcast with an aim to improve public awareness of the complexity and reality of addiction, policies, stigma surrounding drug use and drugs scandals in the newspapers by exploring the evidence base. We are all passionate about the drugs and addiction research field and every episode draws upon our collective knowledge and experience, addressing the health, criminal justice, social and individual side to a story. The podcast links the academic world to the public, bridging the gap and filling in the blanks with research evidence that the media have left out. Previous episodes have covered Dry January, Fabric nightclub in London, drug consumption rooms and now it tackles cannabis legalisation.

This episode introduces different policy options of cannabis legislation, providing alternatives to the usual dichotomous choice of prohibition (possession and supply is illegal) or legalisation (cannabis is freely and widely sold). Alternative legislation is discussed; decriminalisation (it is only illegal to supply) and regulation (a government monopoly). In addition, various factors in the legalisation debate are considered, such as psychosis and THC (active chemical that make users feel “stoned”)/CBD (cannabinoid with various potential medical applications) levels and the impact of legalisation on these. Cannabis is made up of the chemicals THC and CBD and emerging evidence suggests that cannabis high in CBD may mean that people experience fewer psychosis-like symptoms when using the drug. Arguably an incentive for controlling the THC/CBD ratios.